electroCore Secures Two New Patents Extending IP Protection to 2039
Event summary
- electroCore received two new U.S. patents on January 28 and February 4, 2026.
- Patents cover vagus nerve stimulation methods and remote therapy monitoring systems.
- Total patent portfolio now exceeds 160 issued U.S. patents with protection extending to 2039.
- Patents safeguard core gammaCore and gammaCore Sapphire platforms and wellness products.
The big picture
electroCore's expanded patent portfolio strengthens its position as a leader in non-invasive vagus nerve stimulation (nVNS) technology. The patents provide a robust barrier to competition, particularly as the company explores new wellness and medical applications. This move aligns with broader industry trends where bioelectronic medicine companies are fortifying their IP to secure long-term market dominance.
What we're watching
- IP Enforcement
- Whether electroCore can maintain exclusivity against competitors like UAB Pulsetto.
- Market Expansion
- How the extended patent protection will support electroCore's entry into new wellness and medical indications.
- Regulatory Dynamics
- The pace at which electroCore can secure international patents to match its U.S. portfolio.